|
|
|
|
Integrated manufacturing platforms standardize viral vector production, reducing complexity, improving scalability, and accelerating the path to GMP manufacturing for cell and gene therapies.
|
|
|
|
|
Platform-based manufacturing uses standardized, pre-qualified workflows and analytics that reduce variability, simplify regulatory submissions, and accelerate the path to commercial success.
|
|
|
|
|
Plug and play platforms can be adapted to different therapeutic genes without starting the development from scratch for each product, making the transfer to GMP as fast and smooth as possible.
|
|
|
|
|
Discover how automation and digitalization are transforming cell and gene therapy through scalable, decentralized manufacturing, enhanced operational efficiency, and smarter market navigation.
|
|
|
|
|
Setting up a CGT product for regulatory viability and long-term commercial success means investing to empower process design, plus on-time planning of PPQ and CPV activities.
|
|
|
|
|
|
|
AGC Biologics scientists have three decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RVV). We develop and manufacture viral vectors that meet clinical and commercial demands for gene therapy products.
|
|
|
